Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306804 | 0.86 | RAB9A (0.65) | NPC1RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL9775789 | 0.84 | ALDH1A1 (0.58) | NPC1RAB9ALMNASMN1; SMN2KMT2A | |
| SCHEMBL11414289 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2KMT2AALDH1A1MEN1 | |
| SCHEMBL21852785 | 0.83 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL17486763 | 0.83 | KMT2A (0.64) | GAAKMT2AALDH1A1MEN1 | |
| SCHEMBL179090 | 0.83 | CCR5 (0.60) | NPC1RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL7355352 | 0.83 | LMNA (0.56) | NPC1RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL10442179 | 0.82 | KMT2A (0.63) | KMT2AALDH1A1MEN1 | |
| SCHEMBL7327512 | 0.82 | NPC1 (0.63) | NPC1RAB9ALMNASMN1; SMN2EPHX2 | |
| SCHEMBL7959722 | 0.82 | NPC1 (0.63) | NPC1RAB9ALMNASMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NPC1 1399/4885RAB9A 2274/4885LMNA 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.